## REFERENCES


1. Butler, D. Time to Put Malaria Control on the Global Agenda. *Nature* **386**(1997): 535-536.
2. Bruce-Chwatt, L. J.; Black, R. H.; Canfield, C. J.; Clyde, D. F.; Peters, W.; and Wernsdorfer, W. H. Preface by the Director-General of WHO. *Chemotherapy of Malaria.* Bruce-Chwatt, L. J. Ed. Geneva: World Health Organization, (1986): 1-3.
3. Lee, M. Malaria in Search of Solutions. *Chemistry in Britain* (1996): 28.
4. Hall, R. P. XIII Malaria. *Protozoology* (1961): 597-623.
5. Pratt, W. B. Chapter 10 The Chemotherapy of Malaria. *Chemotherapy of Infection.* New York: Oxford University Press, (1977): 307-340.
6. Casteel, D. A. Antimalarial Agents. *Burger's Medicinal Chemistry and Drug Discovery.* 5th ed. New York: John wiley & Sons, **5**(1997): 4-91.
7. Mann, J. Antiparasitic Agents. *Murder, Magic, and Medicine.* Oxford: Oxford University Press, (1992): 198-207.
8. Klayman, D. L. Qinghaosu (Artemisinin): An Antimalaria Drug from China. *Science* **228**(1985): 1049-1055.
9. Bai, D. Traditional Chinese Medicines and New Drug Development. *Pure & Appl. Chem.* **65**(1993): 1103-1112.
10. Haynes, R. K.; and Vonwiller, S. C. From Qinghao, Marvelous Herb of Antiquity, to the Antimalarial Trioxane Qinghaosu-and Some Remarkable New Chemistry. *Acc. Chem. Res.* **30**(1997): 73-79.
11. Yuthavong, Y. The Malarial Folate Pathway and Molecular Targets for Antimalarial Development. *J. Sci. Soc. Thailand* **22**(1996): 181-186.
12. Krungkrai, J.; Yuthavong, Y.; and Webster, H. K. Guanosine Triphosphate Cyclohydrolase in *Plasmodium falciparum* and Other *Plasmodium* Spices. *Mol. Biochem. Parasitol.* **17**(1985): 265-276.
13. Blaney, J. M.; Hansch, C.; Silipo, C.; and Vittoria, A. Structure-Activity Relationships of Dihydrofolate Reductase Inhibitors. *Chem. Rev.* **84** (1984): 333-407.
14. Stryer, L. Chapter 25 Biosynthesis of Nucleotides: Deoxythymidylate is Formed

by Methylation of Deoxyuridylate. *Biochemistry*. 3rd ed. New York: W. H. Freeman and Company, (1988): 613-614.

15. Sirawaraporn, W.; Prapunwattana, P.; Sirawaraporn, R.; Yuthavong, Y.; and Santi, D. V. The Dihydrofolate Reductase Domain of *Plasmodium falciparum* Thymidylate Synthase-Dihydrofolate Reductase. *J. Bio. Chem.* **268**(1993): 21637-21644.
16. Carrington, H. C.; Crowther, A. F.; and Stacey, G. J. Synthetic Antimalarials. Part XLIX. The Structure and Synthesis of the Dihydrotriazine Metabolite of Proguanil. *J. Chem. Soc.* (1954): 1017-1031.
17. Mamalis, P.; and Outred, D. J. Di-Hydro Triazine Derivatives. US Patent 3,723,429, (March 27, 1973).
18. Cowman, A. F.; Morry, M. J.; Biggs, B. A.; Cross, G. A. M.; and Foote, S. J. Amino Acid Changes Linked to Pyrmethamine Resistance in the Dihydrofolate Reductase-Thymidylate Synthase Gene of *Plasmodium falciparum*. *Proc. Natl. Acad. Sci. USA* **85**(1988): 9109-9113.
19. Peterson, D. S.; Walliker, D.; and Weilems, T. E. Evidence that a Point Mutation in Dihydrofolate Reductase-Thymidylate Synthase Confers Resistance to Pyrimethamine in Falciparum Malaria. *Proc. Natl. Acad. Sci. USA* **85**(1988): 9144-9118.
20. Hyde, J. E. Point Mutations and Pyrimethamine Resistance in *Plasmodium falciparum*. *Parasitol. Today* **5**(1989): 252-255.
21. Snewin, V. A.; England, S. M.; Sims, P. F. G.; and Hyde, J. E. Characterisation of the Dihydrfolate Reductase-Thymidylate Synthetase Gene from Human Malaria Parasites Highly Resistant to Pyrimethamine. *Gene* **76** (1989): 41-52.
22. Zolg, J. W.; Plitt, J. R.; Chen, G.-X.; and Palmer, S. Point Mutations in the Dihydrofolate Reductase-Thymidylate Synthase Gene as the Molecular Basis for Pyrimethamine Resistance in *Plasmodium falciparum*. *Mol. Biochem. Parasitol.* **36**(1989): 253-262.
23. Foote, S. J.; Galatis, D.; and Cowman, A. F. Amino Acids in the Dihydrofolate Reductase-Thymidylate Synthase Gene of *Plasmodium falciparum* Involved in Cycloguanil Resistance Differ from those Involved in Pyrimethamine Resistance. *Proc. Natl. Acad. Sci. USA* **87**(1990): 3014-3017.

24. Peterson, D. S.; Milhous, W. K.; and Wellems, T. E. Molecular Basis of Differential Resistance to Cycloguanil and Pyrimethamine in *Plasmodium falciparum* Malaria. *Proc. Natl. Acad. Sci. USA* **87**(1990): 3018-3022.

25. Thaithong, S.; Chan, S.-W.; Songsomboon, S.; Wilairat, P.; Seesod, N.; Sueblinwong, T.; Goman, M.; Ridley, R.; and Beale, G. Pyrimethamine Resistant Mutations in *Plasmodium falciparum*. *Mol. Biochem. Parasitol.* **52**(1992): 149-158.

26. Basco, L. K.; De Pecoulas, P. E.; Wilson, C. M.; and Le Bras, J. Point Mutations in the Dihydrofolate Reductase-Thymidylate Synthase Gene and Pyrimethamine and Cycloguanil Resistance in *Plasmodium falciparum*. *Mol. Biochem. Parasitol.* **69**(1995): 135-138.

27. Basco, L. K.; De Pecoulas, P. E.; Le Bras, J.; and Wilson, C. M. *Plasmodium falciparum*: Molecular Characterization of Multidrug-Resistant Cambodian Isolates. *Exp. Parasitol.* **82**(1996): 97-103.

28. Sirawaraporn, W.; Sathikul, T.; Sirawaraporn, R.; Yuthavong, Y.; and Santi, D. V. Antifolate-Resistant Mutants of *Plasmodium falciparum* Dihydrofolate Reductase. *Proc. Natl. Acad. Sci. USA* **94**(1997): 1124-1129.

29. Rastelli, G.; Sirawaraporn, W.; Sompornpisut, P.; Vilaivan, T.; Kamchonwongpaisan, S.; Quarrell, R.; Lowe, G.; Thebtaranonth, Y.; and Yuthavong, Y. Interaction of Pyrimethamine, Cycloguanil, WR99210 and their Analogues with *Plasmodium falciparum* Dihydrofolate Reductase: Structural Basis of Antifolate Resistance. *Bioorg. & Med. Chem.* **8**(2000): 1117-1128.

30. Modest, E. J.; Foley, G. E.; Pechet, M. M.; and Farber, S. A Series of New, Biologically Significant Dihydrotriazines. *J. Am. Chem. Soc.* **74** (1952): 855-856.

31. Modest, E. J. Chemical and Biological Studies on 1,2-Dihydro-*s*-triazines. II. Three-Component Synthesis. *J. Org. Chem.* **26**(1956): 1-13.

32. Modest, E. J.; and Levine, P. Chemical and Biological Studies on 1,2-Dihydro-*s*-triazines. III. Two-Component Synthesis. *J. Org. Chem.* **26**(1956): 14-20.

33. Newman, H.; and Moon, E. L. The Reaction of Schiff Bases with Dicyanodiamide. A New Synthesis of 4,6-Diamino-1,2-dihydro-*sym*-triazines. *J. Org. Chem.* **29**(1964): 2061-2063.

34. Green, J.; McHale, D.; and Mamalis, P. Improvements in or Relating to Triazine Derivatives. Patent Specification 831,252, (March 23, 1960).

35. Mamalis, P.; Green, J.; and McHale, D. Amino-oxy-derivatives. Part II. Some Derivatives of *N*-Hydroxydiguanide. *J. Chem. Soc.* (1960): 229-238.

36. Price, S. A.; Mamalis, P.; McHale, D.; and Green, J. The Antimicrobial Properties of Some α-Amino-oxy-acids, α-Amino-oxy-hydrozides, Alkoxyamines, Alkoxydiguanieds and their Derivatives. *Brit. J. Pharmacol.* **15**(1960): 243-246.

37. Mamalis, P.; Green, J.; Outred, D. J.; and Rix, M. Amino-oxy-derivatives. Part III. Dihydrotriazines and Related Heterocycles. *J. Chem. Soc.* (1962): 3915-3926.

38. Mamalis, P.; Green, J.; Outred, D. J.; and Rix, M. J. Amino-oxy-derivatives. Part V. Some O-Ethers of 2-Substituted 4,6-Dianino-1,2-dihydro-1-hydroxy-1,3,5-triazines. *J. Chem. Soc.* (1965): 1829-1843.

39. Sirawaraporn, W.; Prapunwattana, P.; Sirawaraporn, R.; Yuthavong, Y.; and Santi, D. V. The Dihydrofolate Reductase Domain of *Plasmodium falciparum* Thymidylate Synthase-Dihydrofolate Reductase: Gene Synthesis, Expression, and Anti-Folate Resistant Mutants. *J. Biol. Chem.* **268**(1993): 21637-21644.

40. Segal, I. H. Behavior and Analysis of Steady-State and Rapid Equilibrium Enzyme Systems. *In Enzyme Kinetics.* Segal, I. H. Ed. New York: Wiley-Interscience, (1975): 100-160.

41. Vilaivan, T.; and Saesaengseerung, N., unpublished results.

42. Baker, B. R.; and Beng-Thong Ho Analogs of Tetrahydrofolic Acid. XXIII. 1-(ω-Phenylalkyl)-4,6-diamino-1,2-dihydro-*s*-triazines as Inhibitors of Dihydrofolic Reductase (1,2). *J. Heterocycl. Chem.* **2**(1965): 72-79.

43. Shapiro, S. L.; Parrino, V. A.; and Freedman, L. Hypoglycemic Agents. III. *N*-Alkyl- and Araylkylbiguanides. *J. Am. Chem. Soc.* **81**(1959): 3728-3735.

44. Vilaivan, T., unpublished results.

# APPENDIX




**Figure 1** $^{1}$H NMR spectrum ($D_2O$) of 1-phenyl-2-methyl-4,6-diamino-1,2-Dihydro-1,3,5-triazine hydrochloride **(II-6)**




**Figure 2** $^{1}$H NMR spectrum ($D_2O$) of 1-phenyl-2-ethyl-4,6-diamino-1,2-dihydro-1,3,5-triazinehydrochloride **(II-7)**




**Figure 3** $^{1}$H NMR spectrum ($D_2O$) of 1-phenyl-2-isopropyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-9)**




**Figure 4** $^{1}$H NMR spectrum ($D_2O$) of 1-phenyl-2-butyl-4,6-diamino-1,2-dihydro-1,3,5-triazinehydrochloride **(II-10)**




**Figure 5** $^{1}$H NMR spectrum ($D_2O$) of 1-phenyl-2-cyclohexyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-11)**




**Figure 6** $^{1}$H NMR spectrum ($D_2O$) of 1-(4'-methylphenyl)-2-methyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-13)**




**Figure 7** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-methylphenyl)-2-ethyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-14)**




**Figure 8** $^{1}$H NMR spectrum ($D_2O$) of 1-(4'-methylphenyl)-2-propyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-15)**




**Figure 9** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-methylphenyl)-2-isopropyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-16)**




**Figure 10** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-methylphenyl)-2-butyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-17)**




**Figure 11** $^{1}$H NMR spectrum ($D_2O$) of 1-(4'-methylphenyl)-2-cyclohexyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-18)**




**Figure 12** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-methylphenyl)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-19)**




**Figure 13** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-ethylphenyl)-2-methyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-20)**




**Figure 14** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-ethylphenyl)-2-ethyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-21)**




**Figure 15** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-ethylphenyl)-2-propyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-22)**




**Figure 16** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-ethylphenyl)-2-isopropyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-23)**




**Figure 17** $^{1}$H NMR spectrum ($D_2O$) of 1-(4'-ethylphenyl)-2-butyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride (**II-24**)




**Figure 18** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-ethylphenyl)-2-cyclohexyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-25)**




**Figure 19** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-ethylphenyl)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-26)**




**Figure 20** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-chlorophenyl)-2-butyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-31)**




**Figure 21** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-chlorophenyl)-2-cyclohexyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-32)**




**Figure 22** $^{1}H$ NMR spectrum ($D_2O$) of 1-(4′-bromophenyl)-2-methyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-34)**




**Figure 23** $^{1}$H NMR spectrum ($D_2O$) of 1-(4'-bromophenyl)-2-ethyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-35)**




**Figure 24** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-bromophenyl)-2-propyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-36)**




**Figure 25** $^{1}$H NMR spectrum ($D_2O$) of 1-(4′-bromophenyl)-2-isopropyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-37)**




**Figure 26** $^{1}H$ NMR spectrum ($D_2O$) of 1-(4′-bromophenyl)-2-butyl-4,6-diamino-i,2-dihydro-1,3,5-triazine hydrochloride **(II-38)**




**Figure 27** $^{1}$H NMR spectrum ($D_2O$) of 1-(4'-bromophenyl)-2-cyclohexyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-39)**




**Figure 28** $^{1}$H NMR spectrum ($D_2O$) of 1-(4'-bromophenyl)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-40)**




**Figure 29** $^{1}$H NMR spectrum ($D_2O$) of 1-(3'-chlorophenyl)-2-isopropyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-44)**




**Figure 30** $^{1}$H NMR spectrum ($D_2O$) of 1-(3′-chlorophenyl)-2-butyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-45)**




**Figure 31** $^{1}$H NMR spectrum ($D_2O$) of 1-(3′-chlorophenyl)-2-pentyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-46)**




**Figure 32** $^{1}$H NMR spectrum ($D_2O$) of 1-(3′-chlorophenyl)-2-heptyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-47)**




**Figure 33** $^{1}$H NMR spectrum ($D_2O$) of 1-(3′-chlorophenyl)-2-cyclohexyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-48)**




**Figure 34** $^{1}$H NMR spectrum ($D_2O$) of 1-(2′,4′-dichlorophenyl)-2-methyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-50)**




**Figure 35** $^{1}$H NMR spectrum ($D_2O$) of 1-(2′,4′-dichlorophenyl)-2-ethyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-51)**




**Figure 36** $^{1}$H NMR spectrum ($D_2O$) of 1-(2′,4′-dichlorophenyl)-2-propyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-52)**




**Figure 37** $^{1}H$ NMR spectrum ($D_2O$) of 1-(2′,4′-dichlorophenyl)-2-isopropyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-53)**




**Figure 38** $^{1}$H NMR spectrum ($D_2O$) of 1-(2′,4′-dichlorophenyl)-2-butyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-54)**




**Figure 39** $^{1}$H NMR spectrum ($D_2O$) of 1-(2′,4′-dichlorophenyl)-2-cyclohexyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-55)**




**Figure 40** $^{1}$H NMR spectrum ($D_2O$) of 1-(3′,4′-dichlorophenyl)-2-butyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-61)**




**Figure 41** $^{1}$H NMR spectrum ($D_2O$) of 1-(3′,4′-dichlorophenyl)-2-pentyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-62)**




**Figure 42** $^{1}$H NMR spectrum ($D_2O$) of 1-(3′,4′-dichlorophenyl)-2-heptyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-63)**




**Figure 43** $^{1}H$ NMR spectrum ($D_2O$) of 1-(3′,4′-dichlorophenyl)-2-cyclohexyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-64)**




**Figure 44** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(2′-methoxyphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-73)**




**Figure 45** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(3′-methoxyphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-74)**




**Figure 46** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(4′-methoxyphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-75)**




**Figure 47** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(2′,4′-dimethoxyphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-76)**




**Figure 48** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(2′,5′-dimethoxyphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-77)**




**Figure 49** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(3′,4′-dimethoxyphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-78)**




**Figure 50** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(3′,5′-dimethoxyphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-79)**




**Figure 51** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(3′,4′,5′-trimethoxyphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-80)**




**Figure 52** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(3′-fluorophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-81)**




**Figure 53** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(4′-fluorophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-82)**




**Figure 54** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(2′-chlorophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-83)**




**Figure 55** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(3′-chlorophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-84)**




**Figure 56** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(4′-chlorophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacet **(II-85)**




**Figure 57** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(2′,4′-dichlorophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-86)**




**Figure 58** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(2′,6′-dichlorophenyl)-4,5-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-87)**




**Figure 59** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(3′,4′-dichlorophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-88)**




**Figure 60** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(2′-bromophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-89)**




**Figure 61** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(4′-bromophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine tifluoroacetate **(II-90)**




**Figure 62** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(3′-nitrophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-91)**




**Figure 63** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(4′-nitrophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-92)**




**Figure 64** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(4′-cyanophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-93)**




**Figure 65** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(2′-chloro-5′-nitrophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-94)**




**Figure 66** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(4′-chloro-3′-nitrophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-95)**




**Figure 67** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(2′-chloro-6′-fluorophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-96)**




**Figure 68** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(4′-*tert*-butylphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-97)**




**Figure 69** $^{1}$H NMR spectrum (DMSO) of 1-benzyl-2-(3′-phenoxyphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-110)**




**Figure 70** $^{1}$H NMR spectrum (DMSO) of 1-phenylethyl-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-99)**




**Figure 71** $^{1}$H NMR spectrum (DMSO) of 1-phenylpropyl-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-100)**




**Figure 72** $^{1}$H NMR spectrum (DMSO) of 1-methoxypropyl-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-101)**




**Figure 73** $^{1}$H NMR spectrum (DMSO) of 1-propyl-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-102)**




**Figure 74** $^{1}$H NMR spectrum (DMSO) of 1-isopropyl-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-103)**




**Figure 75** $^{1}$H NMR spectrum (DMSO) of 1-isobutyl-2-phenyl-4,6-diamino-1,2-Dihydro-1,3,5-triazine trifluoroacetate **(II-104)**




**Figure 76** $^{1}$H NMR spectrum (DMSO) of 1-heptyl-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-105)**




**Figure 77** $^{1}$H NMR spectrum (DMSO) of 1-decyl-2-phenyl-4,6-diamino-1,2- dihydro-1,3,5-triazine trifluoroacetate **(II-106)**




**Figure 78** $^{1}$H NMR spectrum (DMSO) of 1-tetradecyl-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-107)**




**Figure 79** $^{1}$H NMR spectrum (DMSO) of 1-octadecyl-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-108)**




**Figure 80** $^{1}$H NMR spectrum (DMSO) of 1-cyclohexyl-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-109)**




**Figure 81** $^{1}$H NMR spectrum (DMSO) of 1-phenylpropyl-2-(3′-phenoxyphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-111)**




**Figure 82** $^{1}$H NMR spectrum (DMSO) of 1-decyl-2-(3′-phenoxyphenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-112)**




**Figure 83** $^{1}$H NMR spectrum (DMSO) of 1-(3′-morpholin-4′-ylpropyl)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-113)**




**Figure 84** $^{1}$H NMR spectrum (DMSO) of bis-(2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazin-1-yl)ethane bistrifluoroacetate **(II-119)**




**Figure 85** $^{1}$H NMR spectrum ($CDCl_3$) of [2-(2′,4′,5′-trichlorophenyl)ethyl]carbamic acid *tert*-butyl ester **(II-120c)**




**Figure 86** $^{1}$H NMR spectrum ($CDCl_3$) of of [3-(2′,4′,5′-trichlorophenoxy)propyl]carbamic acid *tert*-butyl ester **(II-121c)**




**Figure 87** $^{1}$H NMR spectrum ($CDCl_3$) of of 3-(2′,4′,5′-trichlorophenoxy)propylamine hydrochloride **(II-121d)**




**Figure 88** $^{1}$H NMR spectrum (DMSO) of 1-[2′-(2″,4″,5″-trichlorophenoxy)ethyl]-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate **(II-120)**




**Figure 89** $^{1}$H NMR spectrum (DMSO) of 1-[3′-(2″,4″,5″-trichlorophenoxy)propyl]-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine trifluoroacetate (**II-121**)




**Figure 90** $^{1}$H NMR spectrum (DMSO) of 1-benzyloxy-2-ethyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-124)**




**Figure 91** $^{1}$H NMR spectrum (DMSO) of 1-benzyloxy-2-heptyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride **(II-125)**




**Figure 92** $^{1}$H NMR spectrum (DMSO) of 1-phenethyloxy-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-129)**




**Figure 93** $^{1}$H NMR spectrum (DMSO) of 1-(3′-phenylpropoxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-130)**




**Figure 94** $^{1}$H NMR spectrum (DMSO) of 1-(2′-bromobenzyloxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-131)**




**Figure 95** $^{1}$H NMR spectrum (DMSO) of 1-(3'-bromobenzyloxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-132)**




**Figure 96** $^{1}$H NMR spectrum (DMSO) of 1-(4′-bromobenzyloxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-133)**




**Figure 97** $^{1}$H NMR spectrum (DMSO) of 1-(4′-methylbenzyloxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-134)**




**Figure 98** $^{1}$H NMR spectrum (DMSO) of 1-(naphthalen-2′-ylmethoxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-135)**




**Figure 99** $^{1}$H NMR spectrum (DMSO) of 1-(1′-methoxycarbonylmethoxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-136)**




**Figure 100** $^{1}$H NMR spectrum (DMSO) of 1-allyloxy-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-137)**




**Figure 101** $^{1}$H NMR spectrum (DMSO) of 1-propoxy-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-138)**




**Figure 102** $^{1}$H NMR spectrum (DMSO) of 1-pentyloxy-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-139)**




**Figure 103** $^{1}$H NMR spectrum (DMSO) of 1-decyloxy-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-140)**




**Figure 104** $^{1}$H NMR spectrum (DMSO) of 1-isobutoxy-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-141)**




**Figure 105** $^{1}$H NMR spectrum (DMSO) of 1-(3′-methylbutoxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-142)**




**Figure 106** $^{1}$H NMR spectrum (DMSO) of 1-cyclohexylmethoxy-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-143)**




**Figure 107** $^{1}$H NMR spectrum (DMSO) of 1-(3'-bromopropoxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-144)**




**Figure 108** $^{1}$H NMR spectrum (DMSO) of 1-(2′-phenoxyethoxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-145)**




**Figure 109** $^{1}$H NMR spectrum (DMSO) of 1-(3′-phenoxypropoxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-146)**




**Figure 110** $^{1}$H NMR spectrum (DMSO) of 1-[3′-(4″-chlorophenoxy)propoxy]-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-147)**




**Figure 111** $^{1}$H NMR spectrum (DMSO) of 1-[3′-(4″-methoxycarbonylphenoxy)propoxy]-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-148)**




**Figure 112** $^{1}$H NMR spectrum (DMSO) of 1-[3′-(4″-acetamidophenoxy)propoxy]-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-149)**




**Figure 113** $^{1}$H NMR spectrum (DMSO) of 1-[3′-(biphenyl-4″-yloxy)propoxy]-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-150)**




**Figure 114** $^{1}$H NMR spectrum (DMSO) of 1-(3′-phenylthiopropoxy)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrobromide **(II-151)**

2738 J. Med. Chem. 2000, 43, 2738−2744

# Development of a Lead Inhibitor for the A16V+S108T Mutant of Dihydrofolate Reductase from the Cycloguanil-Resistant Strain (T9/94) of *Plasmodium falciparum*†

Yongyuth Yuthavong,[‡] Tirayut Vilaivan,[§] Netnapa Chareonsethakul,[§] Sumalee Kamchonwongpaisan,[‡] Worachart Sirawaraporn,[∥] Rachel Quarrell,[⊥] and Gordon Lowe*[,⊥]

*National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Bangkok 10400, Thailand; Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand; Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand, and The Dyson Perrins Laboratory, Oxford University, South Parks Road, Oxford, OX1 3QY, U.K.*

*Received February 4, 2000*

The Ala16Val+Ser108Thr (A16V+S108T) mutant of the *Plasmodium falciparum* dihydrofolate reductase (DHFR) is a key mutant responsible for cycloguanil-resistant malaria due to steric interaction between Val-16 and one of the C-2 methyl groups of cycloguanil. 4,6-Diamino-1,2-dihydrotriazines have been prepared, in which both methyl groups of cycloguanil are replaced by H or by H and an alkyl or phenyl group, and their inhibition constants against wild-type and mutant DHFR determined. The S108T mutation is considered to decrease cycloguanil binding further through the effect on the orientation of the *p*-chlorophenyl group. By moving the *p*-chloro-substituent to the *m*-position in the chlorophenyl group, the activity against the A16V+S108T mutant enzyme is improved, and this effect is reinforced by the *p*-chloro substituent in the 3,4-dichlorophenyl group. A lead compound has been found with inhibitory activity similar to that of cycloguanil against the wild-type DHFR and about 120-fold more effective than cycloguanil against the A16V+S108T mutant enzyme. The activity of this compound against *P. falciparum* clone (T9/94 RC17) which harbors the A16V+S108T DHFR is about 85-fold greater than cycloguanil.

## Introduction

Despite continued efforts aimed at complete eradication of malaria, the disease remains a major health threat in many areas of the world, especially in tropical and subtropical countries including Africa.[1] The widespread occurrence of drug-resistant *Plasmodium falciparum* suggests that the effectiveness of the few antimalarials currently in use will have a limited life span and has highlighted the urgent need for the discovery and development of novel antimalarial agents aimed at combating the emerging resistant parasites.

Cycloguanil (Cyc) and its closely related compound pyrimethamine (Pyr) are potent inhibitors of *Plasmodium falciparum* dihydrofolate reductase (pfDHFR), one of a few well-defined drug targets for malaria therapy. Both compounds have been extensively employed, either alone or in combination with sulfa-drugs, as prophylactic agents for the treatment of malaria. Unfortunately, resistance of the malaria parasite to the drugs has rapidly emerged and compromised their clinical utility. Analysis of DHFR sequences of several Pyr- and Cyc-resistant *P. falciparum* isolates from different geographical origins with different drug sensitivities revealed that



Cycloguanil



Pyrimethamine



(A)

resistance to Pyr and Cyc is associated with point mutations in the DHFR.[2-7] The mutations in pfDHFR thus far reported are amino acid residues 16, 51, 59, 108, and 164. Mutant pfDHFRs involving mutations at residues 51, 59, 108, and 164 confer cross-resistance to Pyr and Cyc, while those involving mutation at residue 16 (A16V) are resistant to Cyc but susceptible to Pyr. The importance of residue 16 for binding Cyc has been investigated using the mutants obtained via mutagenesis of a synthetic gene.[8] Recently, a three-dimensional homology model of pfDHFR was constructed to aid understanding of the structural basis of antifolate resistance in malaria.[9] The studies led to a hypothesis which proposed that resistance to Cyc is due to a steric clash for Cyc binding as a result of A16V mutation of the pfDHFR, and that mutation of residue 108 (S108T) further reinforces the steric constraint for Cyc binding through displacement of the *p*-chlorophenyl group of the

[1] Abbreviations: Cyc, cycloguanil; Pyr, pyrimethamine; DHFR, dihydrofolate reductase; pf, *Plasmodium falciparum*.

* Address correspondence to Professor Gordon Lowe. Phone: +44 (0)1865 275649. Fax: +44 (0)1865 275674. E-mail: gordon.lowe@chem.ox.ac.uk.

‡ NSTDA Bangkok.

§ Chulalongkorn University.

∥ Mahidol University.

⊥ Oxford University.

10.1021/jm0009181 CCC: $19.00 
Published on Web 07/13/2000

**Scheme 1**



inhibitor from the nicotinamide ring of the cofactor. Validation of the hypothesis was achieved by testing both the wild-type and A16V+S108T mutant pfDHFRs against Cyc analogues devoid of one or both methyl groups.[9]

In this paper, we describe further modifications to the structure of Cyc in a search for more effective inhibitors of A16V+S108T pfDHFR which are also effective against the wild-type enzyme. Given the important roles of A16V and S108T mutations on Cyc binding, we designed and synthesized a number of Cyc analogues in which the groups at C-2 and N-1 were varied, and we tested them against both wild-type and A16V+S108T pfDHFRs. The studies have led to the discovery of a lead which is as effective as Cyc against the wild-type pfDHFR, but is over 120-fold more effective than Cyc against the A16V+S108T mutant enzyme. The relative effectiveness of the lead was also investigated against the resistant *P. falciparum* strain T9/94, a mutant parasite harboring the A16V+S108T mutant enzyme. Its $IC_{50}$ value is 180-fold lower than that of Cyc, and it retains similar activity to Cyc against the wild-type *P. falciparum*.

## Results and Discussion

**Chemical Syntheses.** 4,6-Diamino-1,2-dihydrotriazines, such as Cyc, are generally made in two steps from dicyandiamide and an aniline under acidic conditions to first generate arylbiguanides which are then reacted with an appropriate carbonyl compound in the presence of an acid catalyst to give the 4,6-diamino-1,2-dihydrotriazine substituted at N-1 and C-2.[10,11] The arylbiguanide may be isolated before further reaction, or the two-step procedure may be performed in the same reaction vessel (Scheme 1). This is an attractive feature of the chemistry and lends itself to the techniques of combinatorial chemistry.[12] However, one should be aware that the rate of formation of the biguanides is strongly influenced by the nucleophilicity of the aniline, and for this reason we have chosen to use a parallel synthesis protocol. Previous attempts to prepare the didemethyl analogue of Cyc (**2**) were unsuccessful,[10,11] and we confirm that the standard protocol using formalin or paraformaldehyde does not give the required product. However, when dimethoxymethane is used as the formaldehyde equivalent, the required product is formed in excellent yield. Other Cyc derivatives were prepared according to the literature methods[10,11] without modification, except that in some cases addition of a miscible water scavenger such as triethyl orthoacetate was found to give improved results, although this is rarely necessary when the carbonyl component is an aldehyde.

**Inhibition of Wild-Type and A16V+108T pfDHFRs.** The data in Table 1 summarize the inhibition constant ($K_i$) values of Cyc and analogues in which the substituents at C-2 were varied, while the group at N-1 (*p*-chlorophenyl) was unmodified. As reported previously,[8] Cyc (**1**) binds to the wild-type pfDHFR with the $K_i$ value of ~1.5 nM, but it binds approximately 876-fold less tightly to the A16V+S108T mutant enzyme. On the basis of our working hypothesis, we surmise that the poor binding of Cyc to A16V+S108T enzyme might be attributed to one of the methyl substituents at the C-2 position of Cyc. To test this hypothesis, we designed and synthesized a number of Cyc derivatives in which one substituent at C-2 was H and the other varied from H (**2**), methyl (**3**), ethyl (**4**), *n*-propyl (**5**), *n*-butyl (**6**), isopropyl (**7**), *tert*-butyl (**8**), and phenyl (**9**). The effects of the substituents on binding to both wild-type and A16V+S108T DHFRs were assessed by determination of the ratios of the $K_i$ values for the A16V+S108T mutant enzyme and the wild-type enzyme ($K_i$-mut./$K_i$-wt) as well as their $K_i$ values relative to Cyc. Table 1 shows that the didemethylcycloguanil (**2**), in which both methyl groups at position C-2 were replaced by H, is ~2-fold more effective against the A16V+S108T pfDHFR than Cyc but inhibited the wild-type enzyme ~16-fold less effectively than Cyc. The monomethyl analogue (**3**) has improved binding affinity (~10-fold) for the A16V+S108T DHFR, but was about 2.7-fold less effective than Cyc for the wild-type enzyme. Since the compound tested was a racemic mixture, if only one enantiomer is active, the relative $K_i$ value of the effective enantiomer could be up to twice that of the value shown. If this is the case, the $K_i$ value of Cyc analogue (**3**) for the wild-type enzyme is within the range reported for Cyc.[8]

**Table 1.** Inhibition Constants ($K_i$) of Cyc (**1**) and Its Analogues (A: X = Cl, Y = H) against the Wild-Type and A16V+S108T Mutant DHFRs of *P. falciparum* and Their Growth Inhibition ($IC_{50}$) against *P. falciparum* Clones with Wild-Type (TM4/8.2) and Mutant (T9/94 RC17) Enzymes

| cmpd | $R_1$ | $R_2$ | $K_i$(wt)[a] (nM) | rel. to Cyc | $K_i$(mut.)[b] (nM) | rel. to Cyc | $K_i$(mut.)/ $K_i$(wt) | $IC_{50}$ TM4 (nM) | $IC_{50}$ T9/94 (nM) | $IC_{50}$ ratio T9/94:TM4 |
|---|---|---|---|---|---|---|---|---|---|---|
| **1** | Me | Me | 1.5 ± 0.3[c] | 1.0 | 1314 ± 16[c] | 1 | 876 | 40 ± 12 | 2430 ± 571 | 60.75 |
| **2** | H | H | 24.4 ± 4.3[d] | 16 | 646 ± 77[d] | 0.5 | 26 | 952 | 313 ± 18 | 0.33 |
| **3** | H | Me | 4.1 ± 0.0[d] | 2.7 | 127 ± 14[d] | 0.09 | 31 | 348 ± 144 | 347 ± 116 | 1.00 |
| **4** | H | Et | 3.6 ± 0.0[d] | 2.4 | 189 ± 37[d] | 0.14 | 52 | 40 ± 2 | 486 ± 220 | 12.15 |
| **5** | H | Pr$^n$ | 4.6 ± 0.2 | 3.1 | 107 ± 32 | 0.08 | 23 | 65 | 365 ± 116 | 5.62 |
| **6** | H | Bu$^n$ | 3.7 ± 0.1 | 2.5 | 167 ± 6.0 | 0.1 | 45 | 111 | 250 ± 109 | 2.25 |
| **7** | H | Pr$^i$ | 60.5 ± 10.1 | 40.3 | 1538 ± 345 | 1.2 | 25 | 2908 | 2818 ± 438 | 0.97 |
| **8** | H | Bu$^t$ | 3838 ± 408 | 2558 | 82721 ± 9888 | 63 | 22 | ~25000 | 65386 ± 7516 | <2.6 |
| **9** | H | Ph | 4.5 ± 0.2 | 3.0 | 49 ± 3 | 0.04 | 11 | 27 ± 11 | 44 ± 15 | 1.63 |

[a] Wild-type pfDHFR. [b] A16V+S108T mutant pfDHFR. [c] Data from ref 8. [d] Data from ref 9.

**Table 2.** Inhibition Constants ($K_i$) of Cyc (**1**) and Its Analogues (A: X = Br, Y = H) against the Wild-Type and A16V+S108T Mutant DHFRs of *P. falciparum* and Their Growth Inhibition ($IC_{50}$) against *P. falciparum* Clones with Wild-Type (TM4/8.2) and Mutant (T9/94 RC17) Enzymes

| cmpd | $R_1$ | $R_2$ | $K_i$(wt)[a] (nM) | rel. to Cyc | $K_i$(mut.)[b] (nM) | rel. to Cyc | $K_i$(mut.)/ $K_i$(wt) | $IC_{50}$ TM4 (nM) | $IC_{50}$ T9/94 (nM) | $IC_{50}$ ratio T9/94:TM4 |
|---|---|---|---|---|---|---|---|---|---|---|
| **10** | Me | Me | 1.1 ± 0.2 | 0.7 | 1947 ± 366 | 1.5 | 1770 | 31 | 2759 ± 153 | 89 |
| **11** | H | Me | 5.7 ± 0.5 | 3.8 | 202 ± 17 | 0.15 | 35 | 132 | 277 ± 32 | 2.1 |
| **12** | H | Et | 2.7 ± 0.3 | 1.8 | 99 ± 7.0 | 0.08 | 37 | 68 | 220 ± 96 | 3.24 |
| **13** | H | $Pr^n$ | 2.6 ± 0.8 | 1.7 | 127 ± 11 | 0.1 | 49 | 63 | 250 ± 110 | 3.97 |
| **14** | H | $Pr^i$ | 30 ± 4.0 | 20 | 1195 ± 53 | 0.9 | 40 | 638 | 725 ± 277 | 1.14 |
| **15** | H | Ph | 2.9 ± 1.2 | 1.9 | 90 ± 11 | 0.07 | 31 | 47 ± 8 | 180 ± 62 | 3.86 |

[a] Wild-type pfDHFR. [b] A16V+S108T mutant pfDHFR.

**Table 3.** Inhibition Constants ($K_i$) of Cyc (**1**) and Its Analogues (A: X = Me, Y = H) against the Wild-Type and A16V+S108T Mutant DHFRs of *P. falciparum* and Their Growth Inhibition ($IC_{50}$) against *P. falciparum* Clones with Wild-Type (TM4/8.2) and Mutant (T9/94 RC17) Enzymes

| cmpd | $R_1$ | $R_2$ | $K_i$(wt)[a] (nM) | rel. to Cyc | $K_i$(mut.)[b] (nM) | rel. to Cyc | $K_i$(mut.)/ $K_i$(wt) | $IC_{50}$ TM4 (nM) | $IC_{50}$ T9/94 (nM) | $IC_{50}$ ratio T9/94:TM4 |
|---|---|---|---|---|---|---|---|---|---|---|
| **16** | Me | Me | 1.8 ± 0.2 | 1.2 | 1584 ± 210 | 1.21 | 880 | 65 | 3617 ± 337 | 55.64 |
| **17** | H | Me | 23.0 ± 1.9 | 15 | 185 ± 22 | 0.14 | 7.9 | 462 ± 35 | 464 ± 208 | 1.00 |
| **18** | H | Et | 5.9 ± 0.2 | 3.9 | 128 ± 4.0 | 0.10 | 22 | 273 | 517 ± 419 | 1.89 |
| **19** | H | $Pr^n$ | 13.7 ± 0.8 | 9.1 | 188 ± 12 | 0.14 | 14 | 167 | 152 | 0.91 |
| **20** | H | $Pr^i$ | 167 ± 11 | 111 | 1460 ± 161 | 1.11 | 8.7 | 8223 | 3446 ± 759 | 0.42 |
| **21** | H | Ph | 7.7 ± 2.0 | 5.1 | 170 ± 14 | 0.13 | 22 | 136 ± 8.3 | 39 ± 9 | 0.29 |

[a] Wild-type pfDHFR. [b] A16V+S108T mutant pfDHFR.

**Table 4.** Inhibition Constants ($K_i$) of Cyc (**1**) and Its Analogues (A: $R_1 = R_2 = R$, Y = H) against the Wild-Type and A16V+S108T Mutant DHFRs of *P. falciparum* and Their Growth Inhibition ($IC_{50}$) against *P. falciparum* Clones with Wild-Type (TM4/8.2) and Mutant (T9/94 RC17) Enzymes

| cmpd | R | X | $K_i$(wt)[a] (nM) | rel. to Cyc | $K_i$(mut.)[b] (nM) | rel. to Cyc | $K_i$(mut.)/ $K_i$(wt) | $IC_{50}$ TM4 (nM) | $IC_{50}$ T9/94 (nM) | $IC_{50}$ ratio T9/94:TM4 |
|---|---|---|---|---|---|---|---|---|---|---|
| **1** | Me | Cl | 1.5 ± 0.3[c] | 1.0 | 1314 ± 164[c] | 1.0 | 876 | 40 ± 12 | 2430 ± 571 | 60.75 |
| **22** | Me | H | 20.0 ± 5.2 | 13 | 1375 ± 236 | 1.05 | 69 | 546 | 445 ± 1 | 0.82 |
| **23** | Me | F | 4.6 ± 0.7 | 3.0 | 1633 ± 269 | 1.20 | 355 | 294 | 1001 ± 466 | 3.40 |
| **2** | H | Cl | 24.4 ± 4.3 | 16 | 646 ± 77 | 0.5 | 26 | 952 | 313 ± 18 | 0.33 |
| **24** | H | H | 329 ± 27 | 220 | 585 ± 70 | 0.4 | 1.8 | 11632 | 356 ± 57 | 0.03 |
| **25** | H | F | 270 ± 28 | 180 | 469 ± 71 | 0.4 | 1.7 | 9661 | 312 ± 36 | 0.03 |

[a] Wild-type pfDHFR. [b] A16V+S108T mutant pfDHFR. [c] Data from ref 8.

The $K_i$ values of monoethyl (**4**), mono-*n*-propyl (**5**), and mono-*n*-butyl (**6**) analogues for the wild-type and A16V+S108T pfDHFRs were comparable to that for the monomethyl (**3**) analogue, implying that the C-2 substituents of these analogues did not appreciably influence or improve the binding affinities of the inhibitors compared with analogue **3**. However, as predicted, the $K_i$ values for both wild-type and A16V+S108T pfDHFRs were greatly increased when the C-2 substituents were branched (and therefore bulkier) alkyl groups, as observed with analogues **7** and **8**. Interestingly, analogue **9**, in which one substituent at the C-2 is H and the other a phenyl group, inhibited the A16V+S108T pfDHFR with the $K_i$ value of ~49 nM, a value which is 27-fold lower than that observed for Cyc (**1**). The above results indicate the crucial role of residue 16 for Cyc binding and suggest the importance of the phenyl group at position C-2 for achieving effective inhibition of the A16V+S108T pfDHFR.

To investigate the significance of the *p*-chloro group on the N-1 substituent of Cyc, two series of Cyc analogues were synthesized in which the N-1 *p*-chlorophenyl group is replaced by *p*-bromophenyl and *p*-tolyl groups. Their $K_i$ values against the wild-type and the mutant pfDHFRs are shown in Table 2 and Table 3. Inhibition constants for the wild-type and mutant enzymes by *p*-bromophenyl (**10** to **15**) and *p*-tolyl (**16** to **21**) analogues showed a trend similar to those where the N-1 substituent is *p*-chlorophenyl (Table 1). However, as the *p*-substituent changes in polarity and size, the monophenyl compounds became progressively less effective against the A16V+S108T mutant enzyme; the $K_i$ values for the mutant enzyme of analogues **9**, **15**, and **21** being 49, 90, and 170 nM, respectively.

The contribution of the *p*-chloro substituent toward the binding affinities of the inhibitors to pfDHFRs was investigated. The C-2 substituents of Cyc were either kept unmodified as dimethyl groups or removed (substituted with H), and the *p*-chloro substituent of *p*-chlorophenyl group at N-1 in Cyc was replaced with either H or F. The analogues were then tested against the wild-type and the A16V+S108T mutant pfDHFRs (Table 4). The results in Table 4 revealed that replacement of the *p*-chloro group with H (analogues **22** and **24**) did not affect the $K_i$ values for the A16V+S108T mutant DHFR but substantially increased the $K_i$ values for the wild-type enzyme. Replacement of the chlorine by fluorine, however, resulted in a 3−14-fold decrease in the binding affinities of the inhibitors to the wild-type enzyme (analogues **23** and **25**, Table 4). The data imply that the *p*-chloro substituent of the *p*-chlorophenyl group is important for binding to the wild-type enzyme and that replacement of the chlorine by a smaller group has relatively little effect on the binding of the inhibitor to the A16V+S108T pfDHFR.

We next investigated the Cyc analogues in which an additional chlorine atom was placed at the *m*-position of the *p*-chlorophenyl substituent. The importance of

**Table 5.** Inhibition Constants ($K_i$) of Cyc (**1**) and Its Analogues (A, Y = Cl) against the Wild-Type and A16V+S108T Mutant DHFRs of *P. falciparum* and Their Growth Inhibition ($IC_{50}$) against *P. falciparum* Clones with Wild-Type (TM4/8.2) and Mutant (T9/94 RC17) Enzymes

| cmpd | $R_1$ | $R_2$ | X | $K_i$(wt)[a] (nM) | rel. to Cyc | $K_i$(mut.)[b] (nM) | rel. to Cyc | $K_i$(mut.)/ $K_i$(wt) | $IC_{50}$ TM$_4$ (nM) | $IC_{50}$ T9/94 (nM) | $IC_{50}$ ratio T9/94:TM4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **26** | Me | Me | H | 3.7 ± 0.6 | 2.5 | 340 ± 28 | 0.3 | 92 | 60 ± 13 | 298 ± 54 | 4.97 |
| **27** | Me | Me | Cl | 1.1 ± 0.4 | 0.73 | 130.7 ± 13.4 | 0.1 | 119 | 4 ± 1 | 307 ± 99 | 76.75 |
| **28** | H | Me | H | 10.2 ± 0.6 | 6.8 | 38.7 ± 2.9 | 0.03 | 3.8 | ND[c] | 28 ± 4 | ND[c] |
| **29** | H | Me | Cl | 1.4 ± 0.2 | 0.9 | 17.8 ± 0.8 | 0.014 | 12.7 | 35 | 19 ± 8 | 0.54 |
| **30** | H | Ph | H | 11.7 ± 2.5 | 7.8 | 10 ± 7 | 0.008 | 0.9 | 455 ± 228 | 24 ± 8 | 0.05 |
| **31** | H | Ph | Cl | 1.6 ± 0.2 | 1.1 | 11 ± 1.8 | 0.008 | 6.9 | 40 ± 25 | 29 ± 2 | 0.72 |

[a] Wild-type pfDHFR. [b] A16V+S108T mutant pfDHFR. [c] Not determined.

*m*-chloro substituent was recently shown in Pyr to improve the effectiveness against the C59R+S108N mutant pfDHFR.[13] As shown in Table 5, the Cyc analogue with *m*-chlorophenyl group (**26**) inhibited the wild-type pfDHFR with the $K_i$ value ~2.5 times higher than that of Cyc (**1**), but it was about 3-fold more effective than Cyc against the A16V+S108T mutant enzyme. Replacement of the *p*-chlorophenyl group of Cyc with the 3,4-dichlorophenyl substituent yielded analogue **27**, which was about as effective as Cyc against the wild-type DHFR but inhibited the A16V+S108T mutant enzyme about 10 times better than Cyc. Indeed, analogue **27**, also known as chlorocycloguanil, is a potent inhibitor of wild-type pfDHFR and has been used as an effective agent for the treatment of malaria.[14] Replacing one of the C-2 methyl groups of the *m*-chlorophenyl analogue by H yielded analogue **28** which showed a significant decrease in the $K_i$ value for the A16V+S108T pfDHFR, but the analogue inhibited the wild-type enzyme ~7-fold less effectively than Cyc (**1**). Addition of a chloro group to analogue **28** gave the monomethyl analogue with the 3,4-dichlorophenyl group at position N-1 (**29**). While the $K_i$ value for analogue **29** was similar to that of Cyc (**1**) against the wild-type pfDHFR, the binding affinity for the A16V+S108T enzyme was dramaticaliy improved, being about 73-fold more effective than Cyc.

The effects of *m*-chlorophenyl and 3,4-dichlorophenyl substituents at N-1 were further tested in the most promising lead compound in which the groups at C-2 were H and phenyl (**9**) (Table 1). Analogues **30** and **31** were over 120-fold more effective than Cyc against the A16V+S108T mutant pfDHFR. While analogue **30** was about 8-fold less effective than Cyc against the wild-type enzyme, analogue **31** was about as effective as Cyc (Table 5).

**In Vitro Antiplasmodial Activity.** The activities of the Cyc analogues against *P. falciparum* were tested in vitro, both in the wild-type clone (TM4/8.2) and the Cyc-resistant clone, which harbors the A16V+S108T pfDHFR (T9/94 RC17). The data in Table 1 shows that some of the 2-monosubstituted analogues of Cyc, namely ethyl, *n*-propyl, and phenyl, have $IC_{50}$ values against the wild-type parasite which are comparable to that of the parent compound. Furthermore, all the compounds have relatively low resistance factors (ratios of $IC_{50}$ for T9/94 to TM4) in comparison to Cyc, some with factors of 1 or less. All compounds except for isopropyl and *tert*-butyl derivatives are much more effective than Cyc against the resistant parasite. The most notable compound in Table 1 is the phenyl derivative, which is almost twice as effective against the wild-type parasite and is over 50 times more effective than Cyc against the resistant parasite. The data in Tables 2 and 3 show the same trend as in Table 1, in that the resistance factors for the 2-monosubstituted derivatives are all lower than those for the 2,2-dimethyl parent compounds. All the 2-monosubstituted compounds in Tables 2 and 3 are more effective against the resistant parasite than the parent compounds. However, none of the compounds in Tables 2 and 3 are as effective as the parent compounds against the wild-type parasite.

The Cyc analogues in Table 4, in which the *p*-chloro substituents had been replaced by sterically less demanding groups, have higher $IC_{50}$ values against the wild-type parasite than those for the parent compounds, generally reflecting the higher $K_i$ values. The low values of resistance factors reflect the poor activities against the wild-type parasite rather than relatively high activities against the resistant parasite.

Table 5 shows the effect on the antiplasmodial activities of Cyc analogues in which dimethyl is changed to a 2-monosubstituted group and the *p*-chloro is replaced by an *m*-chloro or 3,4-dichloro group. All the 2-monosubstituted compounds show excellent activities against the resistant parasite, with $IC_{50}$ values approximately 100 times lower than that of Cyc. Both the 2-monosubstituted and the 3,4-dichlorophenyl derivatives (**29** and **31**) have comparable activities to Cyc against the wild-type parasite.

Preliminary results on human DHFR with some 2-monosubstituted analogues of Cyc show relatively high $K_i$ values (data not shown), suggesting that these compounds are probably of low toxicity and therefore might be suitable for further investigation as lead compounds in the search for new effective antimalarials against antifolate-resistant *P. falciparum*.

## Conclusions

1-(3′,4′-Dichlorophenyl)-2-monosubstituted-4,6-diamino-1,2-dihydro-1,3,5-triazines (**29** and **31**) are useful lead compounds, being at least as effective against the mutant resistant *P. falciparum* strain (T9/94 RC17) as against the wild-type strain (TM4/8.2). They are as effective as Cyc against the wild-type strain of *P. falciparum* and approximately 100-fold more effective than Cyc against the resistant *P. falciparum* strain (T9/94 RC17).

## Experimental Section

**Methods and Materials.** *m*-Chloroaniline was distilled under reduced pressure before use. All other chemicals were obtained from Sigma-Aldrich Ltd., Lancaster, Avocado Ltd., BDH, or other standard suppliers, and they were used without further purification. Reagent grade acetone and absolute alcohol were used.

**Table 6.** Tabulated Elemental, Mass, and NMR Analysis Data for Cyc Analogues **1**–**31**

| cpd | X | Y | $R_1$ | $R_2$ | yd% | anal. | formula | $MH^+$ [a] | NMR details (200 MHz unless otherwise specified) |
|---|---|---|---|---|---|---|---|---|---|
| **1** | Cl | H | Me | Me | 62 | CHN | $C_{11}H_{15}N_5Cl_2$ | 252 (iii) | $^1$H ($D_2O$, 400 MHz) 1.38 (6H, s, 2 × Me), 7.35 and 7.54 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C–H) |
| **2** | Cl | H | H | H | 79 | CHN | $C_9H_{11}N_5Cl_2$ | 224 (i) | $^1$H (DMSO-$d_6$) 4.71 (2H, s, $CH_2$), 6.98 (1H, s br ex, NH), 7.48 (4H, dd, $J_{AB}$ = 8, Ar-C-H), 7.65 (2H, s, $NH_2$), 7.85 (1H, s br ex, NH), 8.74 (1H, s, $NH^+$) |
| **3** | Cl | H | H | Me | 49 | CHN | $C_{10}H_{13}N_5Cl_2$ | 238 (i) | $^1$H ($D_2O$) 1.20 (3H, d, $J$ = 6 Hz, Me-2), 5.06 (1H, q, $J$ = 6 Hz, H-2), 7.22 and 7.40 (2 × 2H, AB doublet, $J$ = 8 Hz, Ar-C–H) |
| **4** | Cl | H | H | Et | 92 | CHN | $C_{11}H_{15}N_5Cl_2$ | 252 (ii) | $^1$H ($D_2O$) 0.94 (3H, $J$ = 6.5 Hz, $CH_3$), 1.52 (2H, m, $CH_2$), 4.84 (1H, dd, $J$ = 6.5, 4 Hz, H-2), 7.22 and 7.38 (2 × 2H, AB doublet, $J$ = 8 Hz, Ar-C-H) |
| **5** | Cl | H | H | Pr$^n$ | 86 | HN[b] | $C_{21}H_{17}N_5Cl_2$·$H_2O$ | 266 (ii) | $^1$H ($D_2O$) 0.65 (3H, t, $CH_3$), 1.15 (2H, m, $CH_2$), 1.55 (2H, m, $CH_2$), 4.94 (1H, dd, $J$ = 6, 4 Hz, H-2), 7.25 and 7.42 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H) |
| **6** | Cl | H | H | Bu$^n$ | 89 | CHN | $C_{13}H_{19}N_5Cl_2$·$3.5H_2O$ | 280 (iii) | $^1$H ($D_2O$) 0.60 (3H, t $J$=6.5 Hz, Me), 1.08 (4H, m, 2 × $CH_2$), 1.55 (2H, m, $CH_2$), 4.96 (1H, dd $J$ = 6.5, 4 Hz, H-2) 7.25, 7.40 (2 × 2H, AB doublet, $J$ = 8 Hz, Ar-C-H) |
| **7** | Cl | H | H | Pr$^i$ | 59 | CHN | $C_{12}H_{17}N_5Cl_2$ | 266 (i) | $^1$H ($D_2O$) 0.65 and 0.75 (6H, 2 × d $J$ = 6.8 Hz, 2 × Me), 1.88 (1H, m, $CH$Me$_2$), 4.74 (1H, d $J$ = 2.8 Hz, H-2), 7.24, 7.40 (2 × 2H, AB doublet, $J$ = 8 Hz, Ar-C-H) |
| **8** | C | H | H | Bu$^t$ | 31 | CHN | $C_{13}H_{19}N_5Cl_2$ | 280 (i) | $^1$H ($D_2O$) 0.66 (9H, s, 3 × Me), 4.65 (1H, s, H-2), 7.31 (4H, m, aromatic C-H) |
| **9** | C | H | H | Ph | 55 | CHN | $C_{15}H_{15}N_5Cl_2$ | 300 (iii) | $^1$H ($D_2O$) 5.84 (1H, s, H-2), 6.90 (2H, part of AB doublet, $J$ = 8 Hz, Ar-C-H), 7.05 (7H, m, Ar-C-H) |
| **10** | Br | H | Me | Me | 78 | CHN | $C_{11}H_{15}N_5BrCl$ | 246 (iii) | $^1$H ($D_2O$) 1.28 (6H, s, 2 × Me), 7.16 and 7.58 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H) |
| **11** | Br | H | H | Me | 53 | CHN | $C_{10}H_{13}N_5BrCl$ | 282, 284 (iii) | $^1$H ($D_2O$) 1.16 (3H, d, $J$ = 6 Hz, Me-2), 5.00 (1H, q, $J$ = 6 Hz, H-2), 7.14 and 7.55 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H) |
| **12** | Br | H | H | Et | 93 | CHN | $C_{11}H_{15}N_5BrCl$ | 296, 298 (iii) | $^1$H ($D_2O$) 0.74 (3H, t, $J$ = 6.5 Hz, $CH_3$), 1.50 (2H, m, $CH_2$), 4.92 (1H, dd, $J$ = 6.5, 4 Hz, H-2), 7.20 and 7.50 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H) |
| **13** | Br | H | H | Pr$^n$ | 74 | CHN | $C_{12}H_{17}N_5BrCl$·$H_2O$ | 310, 312 (iii) | $^1$H ($D_2O$) 0.68 (3H, t, $J$ = 6 Hz, $CH_3$), 1.18 (2H, m, $CH_2$), 1.60 (2H, m, $CH_2$), 4.92 (1H, dd, $J$ = 6, 4 Hz, H-2), 7.20 and 7.50 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H) |
| **14** | Br | H | H | Pr$^i$ | 71 | CHN | $C_{12}H_{17}N_5BrCl$ | 310, 312 (iii) | $^1$H ($D_2O$) 0.66 and 0.76 (6H, 2 × d, $J$ = 7 Hz, 2 × Me), 1.88 (1H, m, $CH$Me$_2$), 4.78 (1H, d, $J$ = 3 Hz, H-2), 7.18 and 7.56 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H) |
| **15** | Br | H | H | Ph | 93 | CHN | $C_{15}H_{15}N_5BrCl$ | 344, 346 (iii) | $^1$H ($D_2O$) 5.88 (1H, s, H-2), 6.88 and 7.34 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H), 7.16 (5H, m, aromatic C-H) |
| **16** | Me | H | Me | Me | 59 | CHN | $C_{12}H_{20}N_5OCl$ | 232 (iii) | $^1$H ($D_2O$) 1.26 (6H, s, 2 × Me), 2.20 (3H, s, 4′-Me), 7.08 and 7.25 (2 × 2H, AB doublet, $J$ = 8 Hz, Ar-C-H) |
| **17** | Me | H | H | Me | 27 | CHN | $C_{11}H_{16}N_5Cl$·HCl·$0.7H_2O$ | 218 (iii) | $^1$H ($D_2O$) 1.18 (3H, d, $J$ = 6.5 Hz, Me-2), 2.15 (3H, s, Me-4′), 5.05 (1H, q, $J$ = 6.5 Hz, H-2), 7.08 and 7.20 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H) |
| **18** | Me | H | H | Et | 77 | CHN | $C_{12}H_{18}N_5Cl$ | 232 (iii) | $^1$H ($D_2O$) 0.72 (3H, t, $J$ = 6 Hz, $CH_3$), 1.65 (2H, m, $CH_2$), 2.18 (3H, s, Me-4′), 4.94 (1H, dd, $J$ = 6, 5 Hz, H-2), 7.15 and 7.25 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H) |
| **19** | Me | H | H | Pr$^n$ | 87 | CHN | $C_{13}H_{20}N_5Cl$·HCl | 246 (iii) | $^1$H ($D_2O$) 0.64 (3H, t, $J$ = 7 Hz, $CH_3$), 1.15 (2H, m, $CH_2CH_3$), 1.60 (2H, m, $CH_2CH_2$), 2.18 (3H, s, Me-4′), 4.94 (1H, dd, $J$ = 6, 4 Hz, H-2), 7.12 and 7.22 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H) |
| **20** | Me | H | H | Pr$^i$ | 85 | HN[b] | $C_{13}H_{20}N_5Cl$·HCl·$CH_3OH$ | 246 (iii) | $^1$H ($D_2O$) 0.65 and 0.75 (6H, 2 × d, $J$ = 7 Hz, 2 × Me), 1.88 (1H, m, $CH$Me$_2$), 2.18 (3H, s, Me-4′), 4.82 (1H, d, $J$ = 3 Hz, H-2), 7.12 and 7.22 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H) |
| **21** | Me | H | H | Ph | 58 | CHN | $C_{16}H_{18}N_5Cl$ | 280 (iii) | $^1$H ($D_2O$) 2.16 (3H, s, Me-4′), 5.96 (1H, s, H-2), 6.94 and 7.12 (2 × 2H, AB doublet, $J$ = 8 Hz, aromatic C-H), 7.30 (5H, m, aromatic C-H) |
| **22** | H | H | Me | Me | 67 | CN[d] | $C_{11}H_{16}N_5Cl$ | 218 (iii) | $^1$H ($D_2O$, 400 MHz) 1.45 (6H, s, 2 × Me), 2.25 (2H, q, $J$ = 7 Hz, $CH_2$), 7.40, 7.55 (2 × m, 5H, Ar-C-H) |
| **23** | F | H | Me | Me | 93 | CHN | $C_{11}H_{15}N_5FCl$ | 235 (i) | $^1$H (DMSO-$d_6$) 1.31 (6H, s, 2 × Me), 6.42 (1H, s br ex, NH), 7.29–7.47 (6H, m, Ar-C-H and $NH_2$), 7.67 (1H, s br ex, NH), 9.01 (1H, s, $NH^+$). $^{13}$C (DMSO-$d_6$) 27.6 (2C, 2 × Me), 70.1 (1C, $CMe_2$), 117.4 + 117.9 (2C, Ar-C-F ortho), 131.7 (1C, $CN_3$), 133.0 + 133.2 (2C, Ar-C-F meta), 158.24 (1C, Ar-C-F ipso), 160.1 (1C, $CN_3$), 165.6 (1C, Ar-C-N). $^{19}$F (DMSO-$d_6$, 250 MHz) −112.5 (1F, Ar-F) |
| **24** | H | H | H | H | 85 | CHN | $C_9H_{12}N_5Cl$ | 190 (i) | $^1$H (DMSO-$d_6$) 4.78 (2H, s, $CH_2$), 6.89 (1H, s br ex, NH), 7.34–7.58 (m, 7H, Ar-C-H and $NH_2$), 7.80 (1H, s br ex, NH) 8.58 (1H, s, $NH^+$) |
| **25** | F | H | H | H | 95 | CHN | $C_9H_{11}N_5FCl$ | 208 (i) | $^1$H (DMSO-$d_6$) 1.31 (6H, s, 2 × Me), 6.42 (1H, s br ex, NH), 7.29–7.47 (6H, m, Ar-C-H and $NH_2$), 7.67 (1H, s br ex, NH), 9.01 (1H, s, $NH^+$). $^{13}$C (DMSO-$d_6$) 27.6 (2C, 2 × Me), 70.1 (1C, $CMe_2$), 117.4 + 117.9 (2C, Ar-C-F ortho), 131.7 (1C, $CN_3$), 133.0 + 133.2 (2C, Ar-C-F meta), 158.24 (1C, Ar-C-F ipso), 160.1 (1C, $CN_3$), 165.6 (1C, Ar-C-N). $^{19}$F (DMSO-$d_6$, 250 MHz) −112.5 (1F, Ar-F) |
| **26** | H | Cl | Me | Me | 60 | CHN | $C_{11}H_{15}N_5Cl_2$·$0.4H_2O$ | 252 (iii) | $^1$H ($D_2O$) 1.30 (6H, s, 2 × Me), 7.10–7.50 (m, 4H, Ar-C-H) |
| **27** | Cl | Cl | Me | Me | 71 | CHN | $C_{11}H_{14}N_5Cl_3$ | 286 (iii) | $^1$H ($D_2O$, 400 MHz) 1.38 (6H, s, 2 × Me), 7.26 (1H, dd, $J$ = 8.5, 2.6 Hz, Ar-CH), 7.60 (1H, d, $J$ = 2.6 Hz, Ar-CH), 7.65 (d, 1H, $J$ = 8.5 Hz, Ar-C-H) |

**Table 6.** Continued

| cpd | X | Y | $R_1$ | $R_2$ | yd% | anal | formula | MH$^+$ [a] | NMR details (200 MHz unless otherwise specified) |
|---|---|---|---|---|---|---|---|---|---|
| 28 | H | Cl | H | Me | 18 | CHN | $C_{10}H_{13}N_5Cl_2$ | 238 (iii) | $^1$H ($D_2O$) 1.18 (3H, d, $J$ = 6 Hz, Me-2), 4.98 (1H, q, $J$ = 6 Hz, H-2), 7.20, 7.35 (m, 4H, Ar-C-H) |
| 29 | Cl | Cl | H | Me | 76 | CHN | $C_{10}H_{12}N_5Cl_3 \cdot 2HCl \cdot H_2O$ | 272 (iii) | $^1$H ($D_2O$) 1.18 (3H, d, $J$ = 6.5 Hz, Me), 5.04 (1H, q, $J$ = 6.5 Hz, H-2), 7.15 (1H, d, $J$ = 8.5, 2.6 Hz, Ar-C-H), 7.50 (2H, m, Ar-C-H) |
| 30 | H | Cl | H | Ph | 90 | HN[c] | $C_{15}H_{15}N_5Cl_2 \cdot H_2O$ | 300 (iii) | $^1$H ($D_2O$) 5.95 (1H, s, H-2), 6.90–7.30 (m, 9H, Ar-C-H) |
| 31 | Cl | Cl | H | Ph | 63 | CHN | $C_{15}H_{14}N_5Cl_3$ | 334 (iii) | $^1$H ($D_2O$) 5.92 (1H, s, H-2), 6.90 (1H, dd, $J$ = 8.0, 2.5 Hz, Ar-CH), 7.10–7.30 (7H, m, Ar-CH) |

[a] Mass spectrometric methods are (i) APCI+, (ii) ESI, (iii) MALDI-TOF. [b] C calcd 45.0; found 45.6. [c] C calcd 48.0; found 47.5. [d] H calcd 6.4; found 7.0. [e] C calcd 46.4; found 46.9.

Parallel synthesis reactions were performed in a Radley multiple synthesis block of 56 wells, equipped with a "Big Bill" rotating shaker, a water-cooled condensing stage, and a J-KEM programmable thermocouple and controller. Reagents were heated and refluxed in 4 mL capacity ReactiVials equipped with 10 cm condensing tubes inserted into Teflon-coated seals and caps. Reactions involving highly volatile solvents were contained under SubaSeals vented using balloon leaks.

Positive-ion chemical ionization mass spectrometry was carried out as APCI in 1:1 methanol/dichloromethane as carrier solvent (Dyson Perrins Laboratory, University of Oxford). MALDI-TOF mass spectra were recorded on a Bruker Biflex mass spectrometer (Institute of Genetic Engineering and Biotechnology, Chulalongkorn University, Bangkok). ESI spectra were obtained using a Fisons Instrument Trio 2000 mass spectrometer (Department of Chemistry, Chulalongkorn University, Bangkok) operating in ESI mode. Masses given are molecular ions and major fragments only, and they are quoted as *m/z* unless otherwise stated. Elemental analysis (C, H, N) was performed by the Oxford University Inorganic Laboratory service and by Ms. A. Ungpakornkaew on a Perkin-Elmer CHN analyzer model PE2400 series II (Chulalongkorn Research Equipment Centre, Bangkok). Routine $^1$H and $^{13}$C NMR spectra were recorded on a Varian Gemini 200 spectrometer, a Bruker AMX250 spectrometer (both Dyson Perrins Laboratory, Oxford), or a Bruker ACF200 (Chulalongkorn University, Bangkok) operating at 200 MHz ($^1$H) and 50.28 MHz ($^{13}$C). High field NMR experiments were performed on a Bruker DRX400 (400 MHz) (National Science and Technology Development Agency, Bangkok). $^1$H and $^{13}$C chemical shifts are quoted in ppm relative to tetramethylsilane and were internally referenced to the residual protonated solvent signal.

**Chemical Syntheses of 4,6-Diamino-1,2-dihydrotriazine Analogues.** The Cyc derivatives bearing gem-dimethyl groups at the C-2 position were prepared by a three-component condensation reaction between an aromatic amine, dicyandiamide, and acetone in the presence of concentrated aqueous HCl as described in the literature (Scheme 1).[13] When the carbonyl compound is an aldehyde, a two-component condensation between the carbonyl compound (1–2 equiv or as solvent) and an aryl biguanide,[11,15,16] obtained from a reaction between an aromatic amine and dicyandiamide in the presence of HCl as catalyst, or a one-pot reaction in which the biguanide was preformed before reacting with the carbonyl compound was sometimes found to be superior. Derivatives of formaldehyde were prepared in the same way as other aldehydes, except that dimethoxymethane was used as a source of formaldehyde. In most cases the desired products precipitated from the reaction medium (usually ethanol) as the crystalline hydrochloride salt. In cases where the product did not crystallize from the reaction, the solvent was completely removed and the product was precipitated by addition of lithium picrate. The picrate salt so obtained was converted back to the hydrochloride salt by treatment with a strongly basic anion-exchange resin Amberlite IRA400 ($Cl^-$ form). The products were recrystallized from ethanol, methanol, or aqueous alcohols. All Cyc derivatives were characterized by $^1$H NMR, mass spectra (APCI, ESI, or MALDI-TOF), and elemental analysis (CHN). The full detailed analysis and the data of the Cyc analogues are shown in Table 6.

**Enzyme Assays and Inhibition by Cyc Analogues.** The activities of wild-type and A16V+S108T mutant pfDHFRs were determined spectrophotometrically according to the method previously described.[17] The reaction (1 mL) contained 1× DHFR buffer (50 mM TES, pH 7.0, 75 mM $\beta$-mercaptoethanol, 1 mg/mL bovine serum albumin), 100 $\mu$M each of the substrate $H_2$ folate and cofactor NADPH, and an appropriate amount (0.001–0.005 units) of the affinity-purified enzymes. Inhibition of the enzymes by Cyc and its analogues was carried out by determination of the $K_i$ values of the inhibitors for the enzymes by fitting to the equation $IC_{50} = K_i(1 + ([S]/K_m))$,[18] where $IC_{50}$ is the concentration of inhibitor which inhibits 50% of the enzyme activity under the standard assay condition and $K_m$ is the Michaelis constant for the substrate $H_2$folate. The resistance factors which determine the effectiveness of the inhibitor against the mutant pfDHFR over the wild-type enzyme were assessed from the values of the ratios of the $K_i$ for the A16V+S108T mutant enzyme and the wild-type enzyme ($K_i$-mut/$K_i$-wt).

**Drug Screening against *Plasmodium falciparum* in Vitro.** Two clones of *P. falciparum*, TM4/8.2 (wild-type DHFR) and T9/94 RC17 (A16V+S108T DHFR),[19] from diverse sources (generous gifts from the Malaria Research Unit, Chulalongkorn University, Bangkok, Thailand) were maintained continuously in human erythrocytes at 37 °C under 3% $CO_2$ in RPMI 1640 culture media supplemented with 25 mM HEPES, pH 7.4, 0.2% $NaHCO_3$, 40 $\mu$g/mL gentamicin, and 10% human serum.[20] In vitro antimalarial activity was determined by using the [$^3$H]-hypoxanthine incorporation method.[21]

The drugs were initially dissolved in DMSO and diluted with the culture media. Aliquots (25 $\mu$L) of the drug having different concentrations were dispensed into 96-well plates, and 1.5% cell suspension of parasitized erythrocytes with 1–2% parasitemia (200 $\mu$L) were added. The final concentration of DMSO (0.1%) did not affect the growth of the parasite. The mixtures were incubated in a 3% $CO_2$ incubator at 37 °C. After 24 h of incubation, 25 $\mu$L (0.25 $\mu$Ci) of [$^3$H]-hypoxanthine was added to each well, and the parasite cultures were further incubated under the same conditions for 18–24 h prior to harvesting the parasite DNA onto 96-well microplates with built-in glass fiber filters (Unifilter TM plates, Packard, USA). The filters in the plates were air-dried, and then 22 $\mu$L of liquid scintillation fluid (Microscint, Packard) was added. The radioactivity on the filters was then measured using a microplate scintillation counter (TopCount, Packard, USA). The concentration of inhibitor which inhibits 50% of the parasite growth ($IC_{50}$) was determined from the sigmoidal curve obtained by plotting the percentages of [$^3$H]-hypoxanthine incorporation against the concentrations of the drug used.

**Acknowledgment.** This research was supported by grants from the World Health Organization (TDR) to W.S., the European Union (INCO-DC IC18CT970223) to Y.Y. and G.L., the Thailand Research Fund (Contract No. PDF/57/2540) to T.V., and the Thailand TDR (98-1-MAL-22-003) to S.K.

## References

(1) Wirth, D. Malaria: A 21st Century Solution for an Ancient Disease. *Nature Med.* **1998**, *4*, 1360–1362.

(2) Cowman, A. F.; Morry, M. J.; Biggs, B. A.; Cross, G. A. M.; Foote, S. J. Amino Acid Changes Linked to Pyrimethamine Resistance in the Dihydrofolate Reductase-Thymidylate Synthase Gene of *Plasmodium falciparum*. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 9109−9113.
(3) Peterson, D. S.; Walliker, D.; Wellems, T. E. Evidence that a Point Mutation in Dihydrofolate Reductase-Thymidylate Synthase Confers Resistance to Pyrimethamine in Falciparum Malaria. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 9114−9118.
(4) Hyde, J. E. Point Mutations and Pyrimethamine Resistance in *Plasmodium falciparum*. *Parasitol. Today* **1989**, *5*, 252−255.
(5) Foote, S. J.; Galatis, D.; Cowman, A. F. Amino Acids in the Dihydrofolate Reductase-Thymidylate Synthase Gene of *Plasmodium falciparum* Involved in Cycloguanil Resistance Differ from Those Involved in Pyrimethamine Resistance. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 3014−3017.
(6) Peterson, D. S.; Milhous, W. K.; T. E. Wellems. Molecular Basis of Differential Resistance to Cycloguanil and Pyrimethamine in *Plasmodium falciparum* Malaria. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 3018−3022.
(7) Basco, L. K.; Eldin de Pecoulas, P. H.; Wilson, C. M. Le Bras, J. Point Mutations in the Dihydrofolate Reductase Gene as the Molecular Basis for Pyrimethamine and Cycloguanil Resistance in *Plasmodium falciparum*. *Mol. Biochem. Parasitol.* **1995**, *69*, 135−138.
(8) Sirawaraporn, W.; Sathitkul, T.; Sirawaraporn, R.; Yuthavong, Y.; Santi, D. V. Antifolate-Resistant Mutants of *Plasmodium falciparum* Dihydrofolate Reductase. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, *94*, 1124−1129.
(9) Rastelli, G.; Sirawaraporn, W.; Sompornpisut, P.; Vilaivan, T.; Kamchonwongpaisan, S.; Quarrell, R.; Lowe, G.; Thebtaranonth, Y.; Yuthavong, Y. Interactions of Pyrimethamine, Cycloguanil and WR99210 and Their Analogues with *Plasmodium falciparum* Dihydrofolate Reductase: Structural Basis for Antifolate Resistance. *Bioorg. Med. Chem.* **2000**, *8*, 1117−1128.
(10) Modest, E. J. Chemistry and Biological Studies on 1,2-Dihydro-*s*-triazines. II. Three-Component Synthesis. *J. Org. Chem.* **1956**, *21*, 1−13.
(11) Modest, E. J.; Levine, P. Chemical and Biological Studies on 1,2-Dihydro-*s*-triazines. III. Two-component Synthesis. *J. Org. Chem.* **1956**, *21*, 14−20.
(12) Lee, H.-K.; Chui, W.-K. Combinatorial Mixture Synthesis and Biological Evaluation of Dihydrophenyl Triazine Antifolates. *Bioorg. Med. Chem.* **1999**, *7*, 1255−1262.
(13) McKie, J. H.; Douglas, K. T.; Chan, C.; Roser, S. A.; Yates, R.; Read, M.; Hyde, J. E.; Dascombe, M. J.; Yuthavong, Y.; Sirawaraporn, W. Rational Drug Design Approach for Overcoming Drug Resistance: Application to Pyrimethamine Resistance in Malaria. *J. Med. Chem.* **1998**, *41*, 1367−1370.
(14) Curtis, J.; Duraisingh, M. T.; Trigg, J. K.; Mbwana, H.; Warhurst, D. C.; Curtis, C. F. Direct Evidence that Asparagine at Position 108 of the *Plasmodium falciparum* Dihydrofolate Reductase is Involved in Resistance to Antifolate Drugs in Tanzania. *Trans. R. Soc. Trop. Med. Hyg.* **1996**, *90*, 678−680.
(15) Carrington, H. C.; Crowther, A. F.; Staccy, C. J. Synthetic Antimalarials. Part XLIX. The Structure and Synthesis of the Dihydrotriazine Metabolite of Proguanil. *J. Chem. Soc.* **1954**, 1017−1031.
(16) Colebrook, L. D.; Giles, H. G.; Rosowsky, A.; Bentz, W. E.; Fehlner, J. R. Chemical and Biological Studies on 1,2-Dihydro-*s*-triazines. XIX. A Nuclear Magnetic Resonance Investigation of Hindered Internal Rotation in 1-Aryl Derivatives. *Can. J. Chem.* **1976**, *54*, 3757−3765.
(17) Sirawaraporn, W.; Prapunwattana, P.; Sirawaraporn, R.; Yuthavong, Y.; Santi, D. V. The Dihydrofolate Reductase Domain of *Plasmodium falciparum* Thymidylate Synthase-Dihydrofolate Reductase. *J. Biol. Chem.* **1993**, *29*, 21637−21644.
(18) Segel, I. H. In *Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems*; Segal, I. H., Ed.; Wiley-Interscience: New York, 1975; pp 100−160.
(19) Thaithong, S.; Chan, S.-W.; Songsomboon, S.; Wilairat, P.; Seesod, N.; Sueblinwong, T.; Goman, M.; Ridley, R.; Beale, G. Pyrimethamine Resistant Mutations in *Plasmodium falciparum*. *Mol. Biochem. Parasitol.* **1992**, *52*, 149−158.
(20) Trager, W.; Jensen, J. B. Human Malarial Parasites in Continuous Culture. *Science* **1976**, *193*, 673−675.
(21) Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Quantitative Assessment of Antimalarial Activity in vitro by a Semiautomated Microdilution Technique. *Antimicrob. Agents Chemother.* **1979**, *16*, 710−718.

JM0009181

# VITA

Netnapa Charoensetakul was born on June 1, 1975 in Chonburi, Thailand. She received Bachelor Degree of Science in Chemistry from Chulalongkorn University in 1997. Since 1998 she has become a student in Graduate School of Chulalongkorn University studying in Department of Chemistry. She graduated with the Master Degree of Science in 2001.